Unlock instant, AI-driven research and patent intelligence for your innovation.

Liquid composition of modified factor vii polypeptides

A composition and factor technology, which is applied in the direction of non-active ingredients of polymer compounds, drug combinations, blood coagulation/fibrinolysis factors, etc., can solve the problems of pain and discomfort of patients

Inactive Publication Date: 2005-04-13
NOVO NORDISK AS
View PDF11 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Compositions are near isotonic, pH of the composition in the physiologically appropriate range after injection / infusion is desirable, may cause additional pain and discomfort to the patient

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0105] Preparation and Purification of Modified Factor VII Polypeptides:

[0106] Modified Factor VII molecules suitable for formulation according to the invention and their production have been described in WO 92 / 15686, WO 94 / 27631 , WO 96 / 12800 and WO 97 / 47651.

[0107] In general, purified human Factor VIIa is preferably prepared by recombinant DNA techniques, as described by Hagen et al., Proc. ) mentioned.

[0108] Factor VII can also be produced using the methods described by Broze and Majerus, J. Biol. Chem. 255(4):1242-1247, 1980, and Hedner and Kisiel, J. Clin.invest. Factor VII produced by these methods does not contain detectable amounts of other coagulation factors. A further purified Factor VII preparation can be obtained with an additional gel filtration step as a final purification step. Factor VII is then converted to activated Factor Vila using known methods, for example using several different plasma proteins, such as Factor Xlla, IXa or Xa. In addition, ...

Embodiment 1

[0117] A. Determination method

[0118] Aggregate content was determined by non-denaturing size exclusion HPLC. The content of the oxidized form was determined by RP-HPLC. The content of enzymatically degraded forms was determined by RP-HPLC.

[0119] Native size exclusion chromatography was performed on a 7.5×300 mm Waters Protein Pak 300SW column using 0.2M ammonium sulfate, 5% 2-propanol pH 7.0 as the mobile phase. Flow rate: 0.5ml / min. Detection: 215nm. Loading: 25 μg FVIIa.

[0120] Reverse phase HPLC was performed on a proprietary 4.5 x 250 mm butyl bonded silica column with a particle size of 5 μm and a pore size of 300 Å. Column temperature: 70°C. A-buffer: 0.1% v / v trifluoroacetic acid. B-buffer: 0.09% v / v trifluoroacetic acid, 80% v / v acetonitrile. The column was eluted with a linear gradient from X to (X+13)% B in 30 minutes. X was adjusted so that FVIIa elutes at a retention time of approximately 26 minutes. Flow rate: 1.0ml / min. Detection: 214nm. Loadi...

Embodiment 2

[0122] Chemical stability of aqueous formulations of Phe-Phe-Arg chloromethyl ketone-inactivated factor VII (FFR-rFVIIa) containing methionine as an antioxidant

[0123] Two different formulations were prepared. The composition of the preparation is as follows:

[0124] FFR-rFVIIa 2mg / ml

[0125] NaCl 2.8-2.9mg / ml

[0126] CaCl2 , 2H 2 O 1.4-1.5mg / ml

[0127] Glycylglycine 1.3mg / ml

[0128] Methionine 0 or 1mg / ml

[0129] pH 7.0

[0130] Methionine (mg / ml)

[0131] The results showed that the addition of methionine slowed down the oxidation rate of the preparation.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a liquid aqueous composition comprising: (i) a modified Factor VII polypeptide; (ii) an agent suitable for maintaining a pH between about 4.0 and about 8.0; (iii) an anti- an oxidizing agent; and (iv) an agent selected from the group consisting of calcium salts, magnesium salts or mixtures thereof.

Description

field of invention [0001] The present invention relates to liquid aqueous compositions containing modified Factor VII polypeptides, and methods of making and using these compositions. More specifically, the present invention relates to liquid compositions that are stable against chemical and / or physical degradation. Background of the invention [0002] Various factors have been identified to be involved in the blood coagulation process, including Factor VII, a plasma glycoprotein. Haemostasis is initiated by the formation of a complex between tissue factor (TF) exposed to circulating blood after vessel wall injury and FVIIa present in the circulation, which corresponds to approximately 1% of the total FVII protein content. FVII exists mainly as a single-chain zymogen in plasma, which is cleaved by FXa into a two-chain activated form, FVIIa. Recombinant activated factor VIIa (rFVIIa) has been developed as a pro-haemostatic agent. [0003] Modified Factor VII molecules are ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K47/04A61KA61K38/36A61K38/43A61K38/48A61K47/02A61K47/10A61K47/12A61K47/14A61K47/18A61K47/20A61K47/22A61K47/26A61K47/34A61K47/36A61K47/42A61P7/02C07K14/745
CPCA61K9/0019A61K38/4846A61K47/02A61K47/183A61K47/20A61P7/02
Inventor B·L·汉森M·B·詹森T·科菲尔特
Owner NOVO NORDISK AS